Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KRISHNANSU TEWARI

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1205868445
CMS profile
426158
Location
ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$98,763.86

53 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $43,534.72 14
GlaxoSmithKline, LLC. $31,035.51 17
AstraZeneca Pharmaceuticals LP $17,755.44 12
Genmab U.S., Inc. $4,907.74 4
PFIZER INC. $1,155.76 2
Karyopharm Therapeutics Inc. $345.69 3
ABBVIE INC. $29.00 1

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KRISHNANSU TEWARI

NPI 1205868445 · CMS profile ID 426158

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205868445?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KRISHNANSU TEWARI, NPI 1205868445, CMS profile ID 426158. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205868445?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). KRISHNANSU TEWARI, NPI 1205868445, CMS profile ID 426158. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205868445?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
KRISHNANSU TEWARI, NPI 1205868445, CMS profile ID 426158, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1205868445?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

53 matching records · $98,763.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 53 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–53 of 53.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $4,800.0001/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116230731 CMS
GlaxoSmithKline, LLC. $1,600.0001/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116300388 CMS
GlaxoSmithKline, LLC. $4,800.0001/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115943931 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $145,271.16 149
PY2020 $35,834.49 25
PY2021 $53,931.12 33
PY2022 $57,129.28 35
PY2023 $71,316.86 43
PY2024 $98,763.86 53
PY2025 $33,081.29 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $793.41 1
PY2025 Principal investigator $146,906.46 29
PY2024 Recipient $1,079.18 1
PY2024 Principal investigator $321,241.11 37
PY2023 Principal investigator $294,874.44 33
PY2022 Recipient $5,238.06 19
PY2022 Principal investigator $318,304.05 22
PY2021 Recipient $1,829.38 9
PY2021 Principal investigator $458,189.34 26
PY2020 Recipient $2,902.54 2
PY2020 Principal investigator $365,021.74 36
PY2019 Recipient $117.98 1
PY2019 Principal investigator $629,756.72 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $921.78 12/31/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926487
Principal investigator 1 Karyopharm Therapeutics Inc. $1,645.32 08/27/2025 Non-covered Recipient Entity
University Of California At Irvine Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246665630
Principal investigator 1 Karyopharm Therapeutics Inc. $4,500.00 08/18/2025 Non-covered Recipient Entity
University Of California At Irvine Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246665632
Principal investigator 1 Karyopharm Therapeutics Inc. $869.40 08/18/2025 Non-covered Recipient Entity
University Of California At Irvine Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246665636
Principal investigator 1 Roche Products Limited $4,382.40 07/30/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients With Advanced Solid Tumours No dispute reported 06/30/2026 1211667710
Principal investigator 1 Roche Products Limited $4,382.40 07/30/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients With Advanced Solid Tumours No dispute reported 06/30/2026 1211667714
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,691.23 07/22/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270328
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,630.69 06/24/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270298
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,366.30 06/20/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270292
Principal investigator 1 PFIZER INC. $1,963.38 06/18/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A RANDOMIZED OPENLABEL PHASE 3 TRIAL OF TISOTUMAB VEDOTIN VS INVESTIGATORS CHOICE CHEMOTHERAPY IN SECOND OR THIRDLINE RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228712800
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,386.87 06/17/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270270
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $396.00 06/17/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270272
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,222.88 06/17/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270274
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,857.00 06/17/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $990.00 06/17/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270278
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $33,776.16 06/17/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270280
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,620.00 06/17/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270282
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,750.09 06/17/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270284
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $660.00 06/17/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 1B/2 STUDY OF TAK-981 PLUS PEMBROLIZUMAB TO EVALUATE THE SAFETY, TOLERABILITY, AND ANTITUMOR ACTIVITY OF THE COMBINATION IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223270286
Principal investigator 1 Roche Products Limited $10,744.80 05/16/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients With Advanced Solid Tumours No dispute reported 06/30/2026 1211667680
Principal investigator 1 Roche Products Limited $2,963.40 05/16/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients With Advanced Solid Tumours No dispute reported 06/30/2026 1211667683
Principal investigator 1 Roche Products Limited $3,161.40 05/16/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients With Advanced Solid Tumours No dispute reported 06/30/2026 1211667686
Principal investigator 1 Roche Products Limited $3,168.00 05/16/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients With Advanced Solid Tumours No dispute reported 06/30/2026 1211667690
Principal investigator 1 Roche Products Limited $1,656.60 05/16/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients With Advanced Solid Tumours No dispute reported 06/30/2026 1211667696
Principal investigator 1 Roche Products Limited $4,382.40 05/16/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients With Advanced Solid Tumours No dispute reported 06/30/2026 1211667700
Principal investigator 1 Roche Products Limited $3,900.60 05/16/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Phase 1 Study of KSQ-4279 Alone and In Combination In Patients With Advanced Solid Tumours No dispute reported 06/30/2026 1211667706
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 05/15/2025 Non-covered Recipient Entity
University Of California At Irvine Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246665634
Principal investigator 1 Karyopharm Therapeutics Inc. $411.00 01/23/2025 Non-covered Recipient Entity
University Of California At Irvine Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246665638
Recipient Regeneron Pharmaceuticals, Inc. $793.41 01/09/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184123424
Principal investigator 1 Merck Sharp & Dohme LLC $12,450.04 01/08/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926485